The pharmacokinetics of quinapril and its active metabolite, quinaprilat, in patients with various degrees of renal function

Single- and multiple-dose pharmacokinetics of quinapril and its active metabolite, quinaprilat, were determined after oral administration of 20 mg quinapril HCl on day 1 and days 4 through 10 in 17 normotensive subjects with various degrees of renal function. Blood and urine samples were collected over 72- and 24-hour periods, respectively, after the first single dose and last multiple dose for measurement of quinapril and quinaprilat concentrations. The renal clearance of quinapril and quinaprilat decreased with increasing renal insufficiency but did not result in significant changes in quinapril pharmacokinetics in patients with renal impairment. In contrast, quinaprilat maximum plasma concentration, trough and peak steady-state plasma concentrations, area under the plasma concentration-time curve, and half-life increased significantly with increasing renal insufficiency. The disposition of quinapril and quinaprilat was unchanged from single to multiple doses. Small changes in the pharmacokinetic disposition of quinapril, together with a decreased rate of quinaprilat elimination, resulted in increased quinaprilat plasma concentrations following administration of both single and multiple quinapril doses to normotensive patients with renal impairment. Thus, quinapril dosage adjustment may be required in some patients with renal impairment.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. M. LeBlanc, J. F. Dasta, M. C. Pruchnicki, and J. J. Schentag Impact of disease States on the pharmacokinetics and pharmacodynamics of Angiotensin-converting enzyme inhibitors. J. Clin. Pharmacol., September 1, 2006; 46(9): 968 - 980. [Abstract] [Full Text] [PDF]

				J. L. Blumer, S. R. Daniels, W. J. Dreyer, D. Batisky, P. D. Walson, D. Roman, and D. Ouellet Pharmacokinetics of Quinapril in Children: Assessment during Substitution for Chronic Angiotensin-Converting Enzyme Inhibitor Treatment J. Clin. Pharmacol., February 1, 2003; 43(2): 128 - 132. [Abstract] [Full Text] [PDF]